Department of Neurology, Klinikum rechts der Isar, Technische Universität, Munich, Germany.
N Engl J Med. 2012 Jul 12;367(2):115-23. doi: 10.1056/NEJMoa1110740.
Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. Many findings suggest that the disease has an autoimmune pathogenesis; the target of the immune response is not yet known.
We screened serum IgG from persons with multiple sclerosis to identify antibodies that are capable of binding to brain tissue and observed specific binding of IgG to glial cells in a subgroup of patients. Using a proteomic approach focusing on membrane proteins, we identified the ATP-sensitive inward rectifying potassium channel KIR4.1 as the target of the IgG antibodies. We used a multifaceted validation strategy to confirm KIR4.1 as a target of the autoantibody response in multiple sclerosis and to show its potential pathogenicity in vivo.
Serum levels of antibodies to KIR4.1 were higher in persons with multiple sclerosis than in persons with other neurologic diseases and healthy donors (P<0.001 for both comparisons). We replicated this finding in two independent groups of persons with multiple sclerosis or other neurologic diseases (P<0.001 for both comparisons). Analysis of the combined data sets indicated the presence of serum antibodies to KIR4.1 in 186 of 397 persons with multiple sclerosis (46.9%), in 3 of 329 persons with other neurologic diseases (0.9%), and in none of the 59 healthy donors. These antibodies bound to the first extracellular loop of KIR4.1. Injection of KIR4.1 serum IgG into the cisternae magnae of mice led to a profound loss of KIR4.1 expression, altered expression of glial fibrillary acidic protein in astrocytes, and activation of the complement cascade at sites of KIR4.1 expression in the cerebellum.
KIR4.1 is a target of the autoantibody response in a subgroup of persons with multiple sclerosis. (Funded by the German Ministry for Education and Research and Deutsche Forschungsgemeinschaft.).
多发性硬化症是一种中枢神经系统的慢性炎症性脱髓鞘疾病。许多研究结果表明,这种疾病具有自身免疫性发病机制;但免疫反应的靶标尚不清楚。
我们从多发性硬化症患者的血清 IgG 中筛选出能够与脑组织结合的抗体,并观察到在一组患者中 IgG 特异性结合神经胶质细胞。利用以膜蛋白为重点的蛋白质组学方法,我们鉴定出 ATP 敏感性内向整流钾通道 KIR4.1 是 IgG 抗体的靶标。我们使用多种验证策略来确认 KIR4.1 是多发性硬化症自身抗体反应的靶标,并证明其在体内的潜在致病性。
多发性硬化症患者血清中针对 KIR4.1 的抗体水平高于其他神经系统疾病患者和健康供体(两者比较 P<0.001)。我们在两组独立的多发性硬化症或其他神经系统疾病患者中复制了这一发现(两者比较 P<0.001)。对联合数据集的分析表明,397 名多发性硬化症患者中有 186 名(46.9%)、329 名其他神经系统疾病患者中有 3 名(0.9%)存在针对 KIR4.1 的血清抗体,而 59 名健康供体中均不存在。这些抗体与 KIR4.1 的第一细胞外环结合。将 KIR4.1 血清 IgG 注入小脑延髓池的小鼠导致 KIR4.1 表达深度丧失、星形胶质细胞中神经胶质纤维酸性蛋白表达改变以及补体级联在小脑 KIR4.1 表达部位激活。
KIR4.1 是一组多发性硬化症患者自身抗体反应的靶标。(由德国联邦教育研究部和德国科学基金会资助)。